CY1109662T1 - Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης - Google Patents
Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασηςInfo
- Publication number
- CY1109662T1 CY1109662T1 CY20091101326T CY091101326T CY1109662T1 CY 1109662 T1 CY1109662 T1 CY 1109662T1 CY 20091101326 T CY20091101326 T CY 20091101326T CY 091101326 T CY091101326 T CY 091101326T CY 1109662 T1 CY1109662 T1 CY 1109662T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- formula
- suspensions
- motion
- growth factor
- Prior art date
Links
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 2
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I)• και φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις του τύπου (I) αναστέλλουν την ενεργότητα τύπου τυροσινοκινάσης σε υποδοχείς αυξητικών παραγόντων όπως HER1, HER2 και HER4, καθιστώμενες έτσι χρήσιμες ως αντιπολλαπλασιαστικούς παράγοντες. Οι ενώσεις του τύπου (I) είναι επίσης χρήσιμες για την αγωγή άλλων παθήσεων συνδεόμενων με πορείες μεταγωγής σήματος οι οποίες λειτουργούν μέσω υποδοχέων αυξητικών παραγόντων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53333503P | 2003-12-29 | 2003-12-29 | |
| EP04815269A EP1699797B1 (en) | 2003-12-29 | 2004-12-23 | Pyrrolotriazine compounds as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109662T1 true CY1109662T1 (el) | 2014-08-13 |
Family
ID=34748887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101326T CY1109662T1 (el) | 2003-12-29 | 2009-12-21 | Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US7141571B2 (el) |
| EP (2) | EP1699797B1 (el) |
| JP (1) | JP4740878B2 (el) |
| KR (1) | KR100839716B1 (el) |
| CN (1) | CN1922182B (el) |
| AR (1) | AR047076A1 (el) |
| AT (1) | ATE443706T1 (el) |
| AU (1) | AU2004312413C1 (el) |
| BR (1) | BRPI0418231A (el) |
| CA (1) | CA2552107C (el) |
| CL (1) | CL2009001492A1 (el) |
| CY (1) | CY1109662T1 (el) |
| DE (1) | DE602004023324D1 (el) |
| DK (1) | DK1699797T3 (el) |
| ES (1) | ES2331842T3 (el) |
| GE (1) | GEP20105081B (el) |
| HK (1) | HK1088332A1 (el) |
| HR (1) | HRP20090601T1 (el) |
| IL (1) | IL176450A0 (el) |
| MX (1) | MXPA06007038A (el) |
| MY (1) | MY145634A (el) |
| NO (1) | NO20062763L (el) |
| NZ (2) | NZ573544A (el) |
| PE (1) | PE20050679A1 (el) |
| PL (1) | PL1699797T3 (el) |
| PT (1) | PT1699797E (el) |
| RU (1) | RU2373209C2 (el) |
| SI (1) | SI1699797T1 (el) |
| TW (1) | TWI332840B (el) |
| UA (1) | UA89038C2 (el) |
| WO (1) | WO2005066176A1 (el) |
| ZA (1) | ZA200605160B (el) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| WO2003090912A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| US7148348B2 (en) | 2004-08-12 | 2006-12-12 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| TW200635927A (en) * | 2004-12-22 | 2006-10-16 | Bristol Myers Squibb Co | Synthetic process |
| US7358256B2 (en) | 2005-03-28 | 2008-04-15 | Bristol-Myers Squibb Company | ATP competitive kinase inhibitors |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| CN101448506A (zh) * | 2005-12-02 | 2009-06-03 | 拜尔健康护理有限责任公司 | 通过抑制有丝分裂酶激酶治疗癌症的吡咯并三嗪衍生物 |
| US8063208B2 (en) * | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| US20100136137A1 (en) * | 2006-11-01 | 2010-06-03 | Bristol-Meyers Squibb Company | Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound |
| CN101627116B (zh) | 2007-02-08 | 2013-07-10 | 科德克希思公司 | 酮还原酶及其用途 |
| US20090076034A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched bms-690514 |
| AU2008343062B2 (en) * | 2007-12-19 | 2013-03-07 | Genentech, Inc. | 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| JP2010209058A (ja) * | 2008-09-29 | 2010-09-24 | Sumitomo Chemical Co Ltd | １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法 |
| US8445676B2 (en) * | 2008-10-08 | 2013-05-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW201035100A (en) | 2008-12-19 | 2010-10-01 | Cephalon Inc | Pyrrolotriazines as ALK and JAK2 inhibitors |
| JP5662346B2 (ja) | 2009-01-21 | 2015-01-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | 新規二環式抗生物質 |
| JPWO2011013656A1 (ja) * | 2009-07-28 | 2013-01-07 | 宇部興産株式会社 | ピロロ［２，３−ｄ］ピリミジン誘導体 |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基－雜芳基衍生物及其使用方法 |
| NZ603837A (en) | 2010-06-30 | 2014-01-31 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| CN102153558B (zh) * | 2011-02-23 | 2012-11-21 | 扬州永济医药新技术有限公司 | 多靶点抗肿瘤抑制剂2-氨吡咯-三嗪的衍生物及其合成方法 |
| DE102011119127A1 (de) * | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| TW201414737A (zh) | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| SG11201605486WA (en) * | 2014-01-13 | 2016-08-30 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| CN110044998B (zh) * | 2014-05-12 | 2021-12-14 | 奎斯特诊断投资公司 | 通过质谱法定量他莫昔芬及其代谢物 |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| EP3792263B1 (en) * | 2018-05-08 | 2023-03-01 | Medshine Discovery Inc. | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective her2 inhibitors and application thereof |
| WO2021088987A1 (zh) * | 2019-11-08 | 2021-05-14 | 南京明德新药研发有限公司 | 作为选择性her2抑制剂的盐型、晶型及其应用 |
| US20240132521A1 (en) * | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2163399A1 (en) | 1994-11-24 | 1996-05-25 | Katsuhiro Kawano | Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor |
| KR20000035934A (ko) | 1996-08-28 | 2000-06-26 | 디. 제이. 우드, 스피겔 알렌 제이 | 치환된 6,5-헤테로-비사이클릭 유도체 |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| RU2331640C2 (ru) | 1999-05-21 | 2008-08-20 | Бристол-Маерс Сквибб Ко. | Пирролтриазиновые ингибиторы киназ |
| WO2001014378A1 (fr) * | 1999-08-23 | 2001-03-01 | Shionogi & Co., Ltd. | DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2? |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| PL366376A1 (en) | 2000-11-17 | 2005-01-24 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| ES2318122T3 (es) | 2002-04-23 | 2009-05-01 | Bristol-Myers Squibb Company | Compuestos de aril cetona pirrolo-triazina utiles como inhibidores de quinasa. |
| WO2003090912A1 (en) | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| US6894066B2 (en) | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US6933386B2 (en) | 2002-07-19 | 2005-08-23 | Bristol Myers Squibb Company | Process for preparing certain pyrrolotriazine compounds |
| WO2004013145A1 (en) | 2002-08-02 | 2004-02-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
-
2004
- 2004-12-09 MY MYPI20045093A patent/MY145634A/en unknown
- 2004-12-22 US US11/019,901 patent/US7141571B2/en active Active
- 2004-12-22 TW TW093140035A patent/TWI332840B/zh not_active IP Right Cessation
- 2004-12-23 NZ NZ573544A patent/NZ573544A/en unknown
- 2004-12-23 DE DE602004023324T patent/DE602004023324D1/de active Active
- 2004-12-23 AU AU2004312413A patent/AU2004312413C1/en not_active Ceased
- 2004-12-23 WO PCT/US2004/043169 patent/WO2005066176A1/en active Application Filing
- 2004-12-23 PL PL04815269T patent/PL1699797T3/pl unknown
- 2004-12-23 RU RU2006127396/04A patent/RU2373209C2/ru not_active IP Right Cessation
- 2004-12-23 DK DK04815269T patent/DK1699797T3/da active
- 2004-12-23 ES ES04815269T patent/ES2331842T3/es active Active
- 2004-12-23 EP EP04815269A patent/EP1699797B1/en active Active
- 2004-12-23 EP EP09153694A patent/EP2058314A1/en not_active Withdrawn
- 2004-12-23 GE GEAP20049544A patent/GEP20105081B/en unknown
- 2004-12-23 UA UAA200608400A patent/UA89038C2/ru unknown
- 2004-12-23 CA CA2552107A patent/CA2552107C/en not_active Expired - Fee Related
- 2004-12-23 KR KR1020067012936A patent/KR100839716B1/ko not_active IP Right Cessation
- 2004-12-23 NZ NZ548070A patent/NZ548070A/en unknown
- 2004-12-23 PT PT04815269T patent/PT1699797E/pt unknown
- 2004-12-23 JP JP2006547328A patent/JP4740878B2/ja not_active Expired - Fee Related
- 2004-12-23 MX MXPA06007038A patent/MXPA06007038A/es active IP Right Grant
- 2004-12-23 AT AT04815269T patent/ATE443706T1/de active
- 2004-12-23 BR BRPI0418231-6A patent/BRPI0418231A/pt not_active IP Right Cessation
- 2004-12-23 SI SI200431286T patent/SI1699797T1/sl unknown
- 2004-12-23 CN CN2004800421984A patent/CN1922182B/zh not_active Expired - Fee Related
- 2004-12-29 AR ARP040104947A patent/AR047076A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 PE PE2005000015A patent/PE20050679A1/es not_active Application Discontinuation
-
2006
- 2006-06-13 NO NO20062763A patent/NO20062763L/no not_active Application Discontinuation
- 2006-06-20 IL IL176450A patent/IL176450A0/en unknown
- 2006-06-22 ZA ZA200605160A patent/ZA200605160B/en unknown
- 2006-06-26 US US11/426,479 patent/US7297695B2/en active Active
- 2006-09-19 HK HK06110373.0A patent/HK1088332A1/xx not_active IP Right Cessation
-
2008
- 2008-09-24 US US11/869,910 patent/US7846931B2/en active Active
-
2009
- 2009-06-26 CL CL2009001492A patent/CL2009001492A1/es unknown
- 2009-11-09 HR HR20090601T patent/HRP20090601T1/hr unknown
- 2009-12-21 CY CY20091101326T patent/CY1109662T1/el unknown
-
2010
- 2010-10-25 US US12/911,299 patent/US20110039838A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109662T1 (el) | Ενωσεις πυρρολοτριαζινης ως αναστολεις κινασης | |
| ATE482212T1 (de) | Pyrrolotriazinverbindungen | |
| TW200420565A (en) | C-6 modified indazolylpyrrolotriazines | |
| ATE349434T1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
| CY1110583T1 (el) | Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων | |
| WO2003042172A3 (en) | C-5 modified indazolylpyrrolotriazines | |
| CY1105253T1 (el) | Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως | |
| CY1109543T1 (el) | Βασικοι μη-πεπτιδικοι ανταγωνιστες βραδυκινινης και 5 φαρμακευτικες συνθεσεις απο αυτους | |
| PT1379520E (pt) | Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| CY1108843T1 (el) | 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων | |
| CY1111656T1 (el) | Παραγωγα αλφα-αμινοαμιδιου χρησιμα εις την θεραπευτικη αγωγη εθιστικων παθησεων | |
| BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| CY1110669T1 (el) | Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| WO2005065266A8 (en) | Di-substituted pyrrolotriazine compounds | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| ATE370147T1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
| PL372769A1 (en) | Cyanoguanidine prodrugs | |
| ATE407133T1 (de) | 2-imidazo-benzothiazole als adenosin-rezeptor liganden | |
| CY1105699T1 (el) | Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας | |
| DE60204882D1 (de) | Zykloalkenylsulfonamidderivate | |
| DE602006004976D1 (de) | Kompetitive atp-kinasehemmer | |
| DE60211018D1 (de) | Fungizide thiazolderivate |